179 related articles for article (PubMed ID: 38072962)
41. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
42. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
[TBL] [Abstract][Full Text] [Related]
43. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Salem K; Brown CO; Schibler J; Goel A
Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
[TBL] [Abstract][Full Text] [Related]
44. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
[TBL] [Abstract][Full Text] [Related]
45. Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.
Han Q; Bai H; Xu Y; Zhou M; Zhou H; Dong X; Chen B
Clin Exp Pharmacol Physiol; 2022 Jun; 49(6):674-685. PubMed ID: 35294057
[TBL] [Abstract][Full Text] [Related]
46. Smart pH-responsive polyhydralazine/bortezomib nanoparticles for remodeling tumor microenvironment and enhancing chemotherapy.
Wang R; Xu X; Li D; Zhang W; Shi X; Xu H; Hong J; Yao S; Liu J; Wei Z; Piao Y; Zhou Z; Shen Y; Tang J
Biomaterials; 2022 Sep; 288():121737. PubMed ID: 36031455
[TBL] [Abstract][Full Text] [Related]
47. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
48. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
[TBL] [Abstract][Full Text] [Related]
49. NCX1/Ca
Li T; Xiao P; Qiu D; Yang A; Chen Q; Lin J; Liu Y; Chen J; Zeng Z
Cell Commun Signal; 2024 May; 22(1):258. PubMed ID: 38711131
[TBL] [Abstract][Full Text] [Related]
50. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
Lipchick BC; Utley A; Han Z; Moparthy S; Yun DH; Bianchi-Smiraglia A; Wolff DW; Fink E; Liu L; Furdui CM; Lee J; Lee KP; Nikiforov MA
Blood Adv; 2021 Apr; 5(7):1933-1946. PubMed ID: 33821992
[TBL] [Abstract][Full Text] [Related]
51. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
52. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
53. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
[TBL] [Abstract][Full Text] [Related]
54. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
55. Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.
Ding K; Jiang W; Jia H; Lei M
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358997
[TBL] [Abstract][Full Text] [Related]
56. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
57. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
[TBL] [Abstract][Full Text] [Related]
59. Sialic Acid Engineered Prodrug Nanoparticles for Codelivery of Bortezomib and Selenium in Tumor Bearing Mice.
Rani S; Sahoo RK; Mahale A; Panchal K; Chaurasiya A; Kulkarni O; Kuche K; Jain S; Nakhate KT; Ajazuddin ; Gupta U
Bioconjug Chem; 2023 Sep; 34(9):1528-1552. PubMed ID: 37603704
[TBL] [Abstract][Full Text] [Related]
60. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]